Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 179

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 179
---
 the clinical laboratory fee schedule, which would increase our billing and collecting costs and decrease our revenue. If we use hazardous materials that cause contamination or injury, or we use them in a manner that causes injury, we could be liable for resulting damages. Our operations currently require the use of hazardous chemicals and biological material, including chemicals, biological agents and compounds and blood and other tissue specimens. Although we typically use licensed or otherwise qualified outside vendors to dispose of this waste, applicable laws and regulations could hold us liable for damages and fines if our or others’ business operations or other actions result in contamination to the environment or personal injury due to exposure to hazardous materials. We cannot eliminate the risk of accidental contamination or injury to employees or third parties from the use, storage, handling or disposal of these materials, and any liability imposed on us for any resulting damages or injury could exceed our resources or any applicable insurance coverage we may have. In addition, a number of governmental bodies have finalized, proposed or are contemplating legislative and regulatory changes in response to the potential effects of climate change. As a result, our expansion and scaling may subject us to stringent sustainability standards, including net zero emissions requirements. The cost of compliance with these laws and regulations and the cost to secure such insurance coverage may become significant in the future, and any failure to comply may result in substantial fines and other business and reputational consequences, any of which could negatively affect our business, financial condition, results of operations or growth prospects. We could be adversely affected by violations of the FCPA and other anti -bribery laws. We are subject to various anti -briberylaws, including the U.S. Foreign Corrupt Practices Act (“FCPA”), and similar anti -briberylaws in the non -U.S. jurisdictions in which we operate. The FCPA prohibits companies and their intermediaries from making payments in violation of law to non -U.S. government officials for the purpose of obtaining or retaining business or securing any other improper advantage. These laws are complex and far -reachingin nature, and we may be required in the future to alter one or more of our practices to be in compliance with these laws or any changes to these laws or their interpretation. We currently conduct a significant portion of our business outside the United States. These operations could involve dealings with governments, foreign officials and state -ownedentities, such as government hospitals, outside the United States. We also may use independent distributors to sell our products internationally. Any such third parties could be deemed to be our